Schwab Charles Investment Management Inc. continued to hold its position in Minerva Neurosciences, Inc (NASDAQ:NERV) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,600 shares of the biopharmaceutical company’s stock at the end of the second quarter. Schwab Charles Investment Management Inc. owned 0.09% of Minerva Neurosciences worth $307,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its stake in shares of Minerva Neurosciences by 54.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 5,579 shares during the period. TD Asset Management Inc. lifted its stake in shares of Minerva Neurosciences by 124.0% in the 2nd quarter. TD Asset Management Inc. now owns 60,693 shares of the biopharmaceutical company’s stock valued at $537,000 after purchasing an additional 33,593 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Minerva Neurosciences by 325.0% in the 1st quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company’s stock valued at $565,000 after purchasing an additional 53,300 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Minerva Neurosciences by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 80,201 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 1,286 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Minerva Neurosciences by 7.9% in the 1st quarter. Geode Capital Management LLC now owns 137,443 shares of the biopharmaceutical company’s stock valued at $1,113,000 after purchasing an additional 10,010 shares during the period. Institutional investors own 69.75% of the company’s stock.

Minerva Neurosciences, Inc (NASDAQ:NERV) opened at $5.10 on Thursday. Minerva Neurosciences, Inc has a one year low of $5.35 and a one year high of $14.15.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter. During the same quarter last year, the firm posted ($0.24) earnings per share. analysts expect that Minerva Neurosciences, Inc will post -1.28 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-maintains-position-in-minerva-neurosciences-inc-nerv/1689302.html.

A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a research note on Tuesday, September 5th. BidaskClub cut Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Finally, Citigroup Inc. started coverage on Minerva Neurosciences in a research note on Friday, September 1st. They issued a “buy” rating and a $11.00 target price for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Minerva Neurosciences has a consensus rating of “Hold” and an average target price of $13.94.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.